Science Explorer Interactive view Map

Gastric Cancer Management and Outcomes

Gastric Cancer Management and Outcomes is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 64k research works in it since 1950. 13.0% of them reached the world's top 10% most cited for their field and year.

This cluster of papers represents a comprehensive exploration of gastric cancer, covering topics such as chemotherapy, endoscopic resection, molecular characterization, lymph node dissection, adjuvant and neoadjuvant therapy, clinical practice guidelines, metastatic gastric cancer, and survival analysis.

  • Gastric Cancer
  • Chemotherapy
  • Endoscopic Resection
  • Molecular Characterization
  • Lymph Node Dissection
  • Adjuvant Therapy
  • Clinical Practice Guidelines
  • Neoadjuvant Chemotherapy
  • Metastatic Gastric Cancer
  • Survival Analysis
Research works
64k
fractional, since 1950
In the world top 10%
8.4k
per year above
Top-10% rate
13.0%
share of its works in the world top 10%
Growth, 2013–17 → 2018–22
+19%
the tick is no change

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Gastric Cancer Management and Outcomes research?

By volume, China and the United States publish the most (3.1k and 2k works in 2022–2025).

By volume, 2022–2025

  1. 1 China 3.1k works
  2. 2 United States 2k works
  3. 3 Japan 1.7k works
  4. 4 South Korea 598 works
  5. 5 United Kingdom 530 works
  6. 6 Italy 438 works
  7. 7 Germany 377 works
  8. 8 India 362 works
  9. 9 Spain 274 works
  10. 10 Russia 250 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 32.3%United States: 21.1%Japan: 17.3%South Korea: 6.2%6 others listed: 23.1%32%largest
China3,126 · 32.3%United States2,042 · 21.1%Japan1,676 · 17.3%South Korea598 · 6.2%6 others listed2,232 · 23.1%

Shares of the rows listed above, not of the whole node.

Which institutions lead Gastric Cancer Management and Outcomes research?

By volume in 2022–2025, Chinese Academy of Medical Sciences & Peking Union Medical College publishes the most Gastric Cancer Management and Outcomes research, followed by Fujian Medical University and Sun Yat-sen University.

Who are the leading researchers in Gastric Cancer Management and Outcomes?

The most-cited researchers publishing on Gastric Cancer Management and Outcomes include Patrick M. Bossuyt, Reza Malekzadeh and Gholamreza Roshandel.

  1. 1 Patrick M. Bossuyt Netherlands 14k citations
  2. 2 Reza Malekzadeh Iran 6.7k citations
  3. 3 Gholamreza Roshandel Iran 5.4k citations
  4. 4 Daniel J. Sargent United States 4.1k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

Where is Gastric Cancer Management and Outcomes research done?

The largest centres of Gastric Cancer Management and Outcomes research in 2022–2025 are Tokyo (Japan), Beijing (China), Seoul (South Korea) and Shanghai (China). Among places with at least 20 works in it, it is an unusually large share of all research in Kashiwa and Plainview.

Largest cities, 2022–2025

  1. 1 Tokyo Japan 412 works
  2. 2 Beijing China 365 works
  3. 3 Seoul South Korea 313 works
  4. 4 Shanghai China 252 works
  5. 5 Guangzhou China 212 works
  6. 6 Nanjing China 151 works
  7. 7 London United Kingdom 148 works
  8. 8 Chengdu China 145 works
  9. 9 New York United States 139 works
  10. 10 Hangzhou China 139 works

Where it is the local speciality

  1. KashiwaJP · 59.9 works54×
  2. PlainviewUS · 33.0 works35×
← less than its size predictsmore →

Location quotient: how much more of its research is in Gastric Cancer Management and Outcomes than the world average.

See Gastric Cancer Management and Outcomes on the map

Where is the best place to study Gastric Cancer Management and Outcomes?

Among universities, judged by research, Fujian Medical University, Humanitas University and Chinese Academy of Medical Sciences & Peking Union Medical College score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 17.49%fractional works in this node (log) →share in the world top 10% →Fujian Medical University: 64, 14.6%Humanitas University: 14, 18.2%Chinese Academy of Medical Sciences & Peking Union Medical College: 82, 14.9%Wakayama Medical University: 11, 18.8%Ulsan College: 16, 18.9%Hebei Medical University: 24, 18.0%Fujita Health University: 10, 18.6%Keio University: 31, 19.2%Harbin Medical University: 22, 16.9%Kitasato University: 13, 16.8%Wakayama Medical Uni…Humanitas UniversityChinese Academy of M…Fujian Medical Unive…
above the meannear itbelow it

One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.

#UniversityScoreTop 10%SpecialisationWorksGrowth
1 Fujian Medical UniversityChina 68.514.6%15.1×64 +126.4%
2 Humanitas UniversityItaly 66.818.2%14.7×14 +437.9%
3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 62.114.9%7.1×82 +97.9%
4 Wakayama Medical UniversityJapan 58.018.8%19.0×11 +138.0%
5 Ulsan CollegeSouth Korea 57.218.9%14.0×16 +45.6%
6 Hebei Medical UniversityChina 56.318.0%9.7×24 +27.5%
7 Fujita Health UniversityJapan 55.818.6%12.8×10 +108.5%
8 Keio UniversityJapan 55.219.2%7.2×31 +48.7%
9 Harbin Medical UniversityChina 54.716.9%9.1×22 +50.9%
10 Kitasato UniversityJapan 53.416.8%11.6×13 +67.7%

Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.

Is Gastric Cancer Management and Outcomes research growing?

Output in 2018–2022 was 19% higher than in 2013–2017, peaking in 2024. The fastest-growing topics are Gastric Cancer Management and Outcomes.

19801990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.